Outcomes summary

Small Phase 2 clinical trial evaluating cibinetide (ARA 290) in diabetic macular edema, reporting no mean improvement in key visual/anatomic endpoints over the study period but suggesting potential signal in some participants, with no serious safety reactions reported in this cohort.

Limitations

Very small sample size; limited control/comparator context; outcomes are exploratory and may be underpowered; industry involvement.

Notes

Primary source: PMID 32674280.